Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The product is used to treat amyotrophic lateral sclerosis
Investing in Malaysia's largest clinic operator to expand the healthcare business
Subscribe To Our Newsletter & Stay Updated
